A recent study evaluating the effects of tofersen treatment in patients with SOD1-ALS in a “real-world setting” (a 12-month multicentre cohort study from the German Early Access Program) confirmed an effective therapeutic approach with a reduction in serum NfL levels, but also demonstrated a reduction in CSF pNFH. Here, SOD1 is linked to amyotrophic lateral sclerosis.